Good MorningEquity markets started the weak on stable footing but could not post substantial gains on Monday. The move is partly due to easing fear of a banking crisis compounded by uncertainty about the PCE data on Friday. The analysts expect core PCE to moderate to 0.4% month-to-month but remain hot at 4.7% YOY. At this level, the FOMC may need to hike interest rates beyond the recently intended target, and there is a risk it will come in hotter than expected.
With only 2 weeks until the start of the Q2 peak earnings reporting cycle, the market is bracing for what could be a very bad season. The consensus target for Q1 earnings is below -6.0% and it could be worse by the end of the season. The details that will more the market are the guidance and outlook for the 2nd half of the year, if those take another hit this market will move one step closer to another major sell-off. Featured: Former Bank Insider Risks Everything To Blow Whistle On Disturbing New Government Program
(IPM) 
|
Stocks | | |
Analysts can be a powerful force in the market. If there are enough of them covering a stock, when their sentiment changes, it will move the stock price. Marketbeat.com’s analyst tracking tools will show 3 names that reported solid results for CQ4, gave positive guidance, and earned a round ... Read the Full Story |
|
From Our PartnersMr. Market is fickle and emotional... After ten years of going up in a nearly unbroken line, he abruptly decided to reverse course...
And usher in a bear market that has crushed portfolios — But while most investors were going through the worst year since the Global Financial Crisis...
A small group of 3,700 people had the chance to collect instant "bonus payouts" courtesy of Mr. Market every week.
| | All thanks to a method most investors have no idea about… watch this demo showing how it works. |
|
Stocks | | |
While the enterprise software makers are in the doldrums, and the financial sector tries to recover from a battering, a few specialty software firms, including Intapp Inc. (NASDAQ: INTA), Vertex Inc. (NASDAQ: VERX), and GuidewIre Software Inc. (NYSE: GWRE) are headed toward greater profitability, ... Read the Full Story |
|
Stocks | | |
For the last year, investors have heard the advice that “cash is king.” Cash is also important when it comes to the companies you choose to invest in. And while this is a difficult market, there are still opportunities for buy-and-hold investors with a suitable time horizon. And the th... Read the Full Story |
|
From Our PartnersIf that sounds too good to be true… trust me, I get it. But one trader has done just that, holding one of the top track records on Wall Street in recent years. Regardless of bull or bear markets his 9/10 win rate has held strong (with no signs of slowing down). Now he wants YOU to have the same opportunity to rack up incredible gains, no matter what the market does next. Still not convinced? | | Click HERE to see it with your own eyes. |
|
Markets | | |
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) is positioned to make a new run at the 52-week high of $325.19 as the stock is confirming a cup base pattern. The biotechnology company’s stock is up 7.3% in the last month and just announced some news that could send the stock much higher.
... Read the Full Story |
|
Markets | | | Asian stocks were mixed Wednesday as anxiety about the global financial system began to fade following three high-profile bank failures.Shanghai followed Wall Street lower. Tokyo and Hong Kong advanced. Oil prices gained.Fears that the global banking system might be cracking under the strain of rapi... Read the Full Story |
|
From Our PartnersIf that sounds too good to be true… trust me, I get it. But one trader has done just that, holding one of the top track records on Wall Street in recent years. Regardless of bull or bear markets his 9/10 win rate has held strong (with no signs of slowing down). Now he wants YOU to have the same opportunity to rack up incredible gains, no matter what the market does next. Still not convinced? | | | | Click HERE to see it with your own eyes. |
|
Markets | | |
Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.68%, following promising news about the companies’ jointly developed medication Dupixent.
In Phase 3 clinical trials, Dupixent reduced severe ... Read the Full Story |
|
Markets | | | If inflation has eaten away at your budget the way waves erode a beach, then your tax refund might just provide a much-needed protective barrier.As of March, prices are up 6% over the past 12 months, according to the most recent consumer price index. At the same time, just over half of filers (55%) ... Read the Full Story |
|
Markets | | | South Dakota's House failed Monday to override Gov. Kristi Noem's recent veto of a bill that would have created government regulations for the use of cryptocurrency in the state. The bill had passed smoothly throughout the legislature, and Noem's veto of last week was upheld on a 37-30 vote.Proponen... Read the Full Story |
|
Markets | | | The Federal Reserve’s bank supervisors warned Silicon Valley Bank’s management as early as the fall of 2021 of risks stemming from its unusual business model, a top Fed official said Tuesday, but its managers failed to take the steps necessary to fix the problems Read the Full Story |
|
Markets | | | Flak jackets are piled up at Ukraine’s Zaporizhstal steel plant, and anti-tank traps guard the entrance. Whenever air raid sirens sound — and they go off every day — most workers head to one of the 16 bomb shelters scattered across the sprawling grounds.But some keep working — braving not only the i... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
